Business Context and Reporting Period
Protagonist Therapeutics, Inc. (PTGX), an emerging growth company incorporated in Delaware, filed this Form 8-K on November 27, 2019. The report discloses the entry into a material definitive agreement to facilitate the sale of common stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a potential equity offering.
Material Changes and Agreements
On November 27, 2019, the Company entered into an Open Market Sale Agreement with Jefferies LLC. Key terms include:
- Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $75,000,000.
- Sales Method: Shares will be sold via "at the market" offerings on The Nasdaq Global Market or other trading venues, subject to Company instructions.
- Compensation: Jefferies will receive a commission of up to 3.0% of the gross sales proceeds.
- Obligation: The Company is not obligated to sell any shares under the agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial performance, or discussion of operational risks beyond the standard legal disclaimers regarding the securities offering. The agreement terminates upon the sale of all shares or earlier termination per its terms.
Investor Verification Checklist
- Verify the current share price and market capitalization to assess the potential dilution impact of a full $75,000,000 offering.
- Review the Company's most recent 10-K or 10-Q to understand current cash runway and liquidity needs driving this financing option.
- Monitor future 8-K filings for actual sales activity and the total proceeds raised under this agreement.
- Confirm the status of the underlying shelf registration statement (File No. 333-234414).